Acrux signs second distribution agreement with CSL
Tuesday, 30 November, 2004
Acrux (ASX: ACR) has signed a second distribution agreement with CSL (ASX: CSL), giving CSL the rights to distribute Acrux's Fentanyl MDTS treatment for severe pain.
The product, which is undergoing Phase I clinical development, will be distributed by CSL Pharmaceuticals in Australia and New Zealand. Acrux will receive both an upfront payment plus royalties on net sales.
Earlier this year, CSL agreed to distribute Acrux's testosterone MDTS treatment for low testosterone levels and sexual dysfunction in women.
Farm animals and aquaculture cryopreservation partnership announced
Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
